AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muñoz Bellido, J. L.
Right arrow Articles by García-Rodríguez, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muñoz Bellido, J. L.
Right arrow Articles by García-Rodríguez, J. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1999, p. 966-968, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Activities of 13 Fluoroquinolones against Staphylococcus aureus Isolates with Characterized Mutations in gyrA, gyrB, grlA, and norA and against Wild-Type Isolates

J. L. Muñoz Bellido,1 M. A. Alonso Manzanares,1 G. Yagüe Guirao,2 M. N. Gutiérrez Zufiaurre,1 M. C. M. Toldos,2 M. Segovia Hernández,2 and J. A. García-Rodríguez1,*

Departamento de Microbiología, Hospital Universitario de Salamanca, Salamanca,1 and Departamento de Microbiología, Hospital General Universitario de Murcia, Murcia,2 Spain

Received 3 August 1998/Returned for modification 9 September 1998/Accepted 5 January 1999

The in vitro activities of 13 fluoroquinolones (FQs) were tested against 90 Staphylococcus aureus clinical isolates: 30 wild type for gyrA, gyrB, grlA and norA and 60 with mutations in these genes. Clinafloxacin (CI-960), sparfloxacin, and grepafloxacin were the most active FQs against wild-type isolates (MICs at which 90% of isolates were inhibited, 0.06 to 0.1 µg/ml). Mutations in grlA did not affect the MICs of newer FQs. grlA-gyrA double mutations led to higher MICs for all the FQs tested. Efflux mechanisms affected the newer FQs to a much lesser extent than the less recently developed FQs.

* Corresponding author. Mailing address: Department of Microbiology, Hospital Universitario de Salamanca, Paseo de San Vicente 108, 7007 Salamanca, Spain. Phone: 34923264825. Fax: 34923262261. E-mail: jagarrod{at}gugu.usal.es.

Antimicrobial Agents and Chemotherapy, April 1999, p. 966-968, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.